Given that asthma affects over 300 million people, many of whom are on treatment with inhaled corticosteroids and may encounter SARS-CoV-2, we evaluated LAE ACE2 expression in a cohort of predominantly mild to moderate nonsmoker asthmatics, treated with maintenance ICS (ICS+) vs not treated (ICS−). This evidence concerns the gene ACE2 and asthma.